As we all know, the maker of EpiPen, Mylan, has engaged in price gouging. But this week, the larger health care industry sent a strong message that they are not going to stand for it. On Wednesday, Cigna announced it would only cover the generic version of EpiPen. On Thursday, CVS announced a deal with an EpiPen competitor that could hurt Mylan’s generic sales. It’s a strange and unusual kind of pushback. The kind we rarely see in the health care industry.
Click the above audio player to hear the full story.
If you’re a member of your local public radio station, we thank you — because your support helps those stations keep programs like Marketplace on the air. But for Marketplace to continue to grow, we need additional investment from those who care most about what we do: superfans like you.
Your donation — as little as $5 — helps us create more content that matters to you and your community, and to reach more people where they are – whether that’s radio, podcasts or online.
When you contribute directly to Marketplace, you become a partner in that mission: someone who understands that when we all get smarter, everybody wins.
make public service
Thank you for doing your part!